CoChat

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

PURPOSE: Several options are available for the treatment of hypertension; however, many treated patients are still not below blood pressure (BP) target. Eplerenone, a selective mineralocorticoid receptor antagonist, is an approved treatment option for the management of patients with hypertension in a number of countries. This patient-level pooled analysis was conducted to document the efficacy and safety/tolerability of eplerenone at the dosages approved for use in hypertension in comparison to placebo or other approved antihypertensive agents. METHODS: Seventeen Phase III studies conducted in patients with mild-to-moderate hypertension in the Eplerenone Hypertension Clinical Program were reviewed; eleven met the selection criteria. The primary endpoint was change from baseline in seated diastolic BP and seated systolic BP measured at the end of the study. RESULTS: < 0.033). In the analysis of covariance model testing of the contribution of four factors (age, body mass index [BMI], history of cardiovascular disease, and diabetes) on the BP lowering effects of eplerenone, only BMI and age were associated with small though statistically significant changes in BP (<0.2 mmHg). Eplerenone was well tolerated; headache was the most common adverse event for patients in any group. Severe hyperkalemia (serum potassium level >6.0 mmol/L) occurred in up to 0.4% in the eplerenone groups, 0.4% in the placebo group, and 0.1% in the active-control group. CONCLUSION: This patient-level pooled analysis provides robust evidence that eplerenone, at 50 mg or 100 mg daily, was effective in lowering BP in patients with mild-to-moderate hypertension and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/vhrm.s170141

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition. (A) Placebo-controlled studies. (B) Active-controlled studies.
Figure 1 Patient disposition. (A) Placebo-controlled studies. (B) Active-controlled studies.CC BY-NC · PubMed Central
Figure 2 Change from baseline in seated SBP/DBP: (A) placebo-controlled studies and (B) active-controlled studies. Notes: LS Means model includes Study, Treatment, and Baseline BP. The per-protocol analysis set included all patients who were randomly assigned to treatment (eplerenone 50 mg daily, eplerenone 100 mg daily, or active control), who had a baseline primary efficacy evaluation, took at least one dose of study drug, and received at least 6 weeks of fixed dose of study drug. Weight of blue symbol is defined as percentage study contribution to total pooled results. Study 015 is not represented in the eplerenone 100 mg analysis due to lack of treatment arm with that dosage. Study 019 is not represented in the eplerenone 50mg analysis due to lack of treatment arm with that dosage. See Table 3 for the 95% confidence intervals of differences in seated SBP/DBP between eplerenone and placebo.
Figure 2 Change from baseline in seated SBP/DBP: (A) placebo-controlled studies and (B) active-controlled studies. Notes: LS Means model includes Study, Treatment, and Baseline BP. The per-protocol analysis set included all patients who were randomly assigned to treatment (eplerenone 50 mg daily, eplerenone 100 mg daily, or active control), who had a baseline primary efficacy evaluation, took at least one dose of study drug, and received at least 6 weeks of fixed dose of study drug. Weight of blue symbol is defined as percentage study contribution to total pooled results. Study 015 is not represented in the eplerenone 100 mg analysis due to lack of treatment arm with that dosage. Study 019 is not represented in the eplerenone 50mg analysis due to lack of treatment arm with that dosage. See Table 3 for the 95% confidence intervals of differences in seated SBP/DBP between eplerenone and placebo.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. [31]Weinberger MH Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am J Hypertens 2002 15 709 716 12160194

Cited by

See all 7

Metadata

Authors
Fernet, M., Beckerman, B., Abreu, P., Lins, K., Vincent, J., & Burgess, E.
Affiliations
  • Pfizer (Canada) (CA)
  • Pfizer (United States) (US)
  • Pfizer (United Kingdom) (GB)
  • University of Calgary (CA)
Corresponding author
Burgess, Ellen
Venue
Vascular Health and Risk Management
Published
2018-09
Volume
Volume 14
Pages
233-246
ISSN
  • 1176-6344 (ISSN-L)
  • 1178-2048
OpenAlex
W2892141990
Cited by
7
References
50
Citations by year
2026: 1 · 2025: 1 · 2023: 2 · 2020: 1 · 2019: 2
FWCI
0.57
Type
journal article
Language
en
Open access
Locations
  • Vascular Health and Risk Management (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
eplerenone, mineralocorticoid receptor antagonists, hypertension, antihypertensive efficacy, blood pressure reduction, hyperkalemia, drug safety and tolerability, body mass index
MeSH terms
Eplerenone, Adult, Aged, Mineralocorticoid Receptor Antagonists, Antihypertensive Agents, Blood Pressure, Female, Humans, Hypertension, Male, Middle Aged, Spironolactone, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. https://app.cochat.ai/papers/10.2147/vhrm.s170141
The paper
Fernet, M., Beckerman, B., Abreu, P., Lins, K., Vincent, J., & Burgess, E. (2018). Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. Vascular Health and Risk Management. https://doi.org/10.2147/vhrm.s170141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.